

Melior Enters Research Collaboration with Pfizer

EXTON, Pa, April 9th, 2007 (BUSINESS WIRE) – Melior Discovery, Inc. announced today that it has signed an agreement with Pfizer, Inc., under which Melior's in-vivo *theraTRACE* indications discovery platform will be used to evaluate the activity of selected Pfizer compounds.

"Our agreement represents a significant opportunity for Melior to deliver value to Pfizer through the application of our unique and innovative *in vivo* testing platform," said Andrew Reaume, PhD, President and CEO of Melior. "We look forward to a productive collaboration."

Melior Discovery Overview

Melior Discovery is leading the transformation of pharmaceutical drug repositioning with its unique *theraTRACE* platform of multiplexed *in vivo* models. It is using this capability to both build an internal pipeline of development candidates as well as sharing this capability with pharma and biotechnology company partners. In the former case, Melior is identifying "privileged" compounds that have been discontinued by others which it identifies through a close working relationship with Dr. Christopher Lipinski. In its partnered arrangements, Melior offers pharmaceutical partners an approach to expand their late-stage pipelines with safe, high-quality drug candidates

Melior Discovery is located in Exton, PA. For more information contact:

Andrew Reaume
President & CEO
Melior Discovery
860 Springdale Drive
Exton, PA 19341

e-mail: areaume@meliordiscovery.com